Palazestrant Clinical Trials (2026): 5 Studies for Metastatic Breast Cancer & Breast Cancer

Where to Participate: All Palazestrant Trial Sites in the U.S. (71 sites across 27 states)

Every actively recruiting Palazestranttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Palazestrant clinical trials at a glance: phase × recruitment status

Recruiting Palazestrant clinical trials (4)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Palazestrant clinical trials by indication

Palazestrant pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All Palazestrant trials (5)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Palazestrant clinical trials: frequently asked questions

How many Palazestrant clinical trials are there?

5 Palazestrant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants.

Are Palazestrant clinical trials recruiting in 2026?

Yes — 4 Palazestrant trials are actively recruiting in 2026, with 71 U.S. sites across 27 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Palazestrant being studied for?

Palazestrant is being studied for Metastatic Breast Cancer, Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma, Locally Advanced Breast Cancer and 8 more. The trials are grouped by indication on this page.

What phase is Palazestrant in?

Palazestrant clinical trials span 2 Phase 3, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Palazestrant clinical trials?

The lead sponsor across the most Palazestrant trials is Olema Pharmaceuticals, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Palazestrantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.